

**MINUTES OF THE REGULAR MEETING
OF THE ENTREPRENEURSHIP COMMITTEE
OF THE BOARD OF THE INDIANA
ECONOMIC DEVELOPMENT CORPORATION**

December 11, 2008

Chairperson Sally Byrn convened a regular meeting of the Entrepreneurship Committee of the Board of the Indiana Economic Development Corporation at 9:37 a.m. on Thursday, December 11, 2008, at the AIT Laboratories, 2265 Executive Drive, Indianapolis, Indiana.

MEMBERS PRESENT: Sally R. Byrn
Cathy Langham
Dane Miller
John Thompson

STAFF PRESENT: Bruce Kidd
Karl Koehler
Linda Peterson-Roe

OTHERS PRESENT: David Gard

WELCOME

The Chair called the meeting to order, recognized the presence of a quorum, noted conformance with State Open Door Policies, and the importance of not exposing during discussion confidential information contained in the proposals upon which the recommended awards are based and confirmed that a member of the public was present.

APPROVAL OF THE AUGUST 27, 2008 MEETING MINUTES

Mr. Thompson moved approval of the minutes of the August 27, 2008 meeting of the Entrepreneurship Subcommittee of the Board, with Ms. Langham seconding. The minutes were unanimously approved.

PRESENTATION OF 21ST CENTURY RESEARCH & TECHNOLOGY FUND APPLICATIONS

Mr. Kidd presented four recommended projects to the Committee for consideration. Mr. Kidd noted that the respective applicants have submitted the information and documentation required under the Fund's Request for Applications and guidelines, that each project conforms with the 21st Century Fund goals and objectives and that staff and the External Peer Review Board have recommended each project to the Committee for its approval.

SonarMed, Inc.
Indianapolis, IN (Marion County)
\$500,000

SonarMed is a medical device company focused on developing novel and innovative products for critical care medicine. Through these products, the company intends to improve the clinical care of patients while reducing healthcare costs. SonarMed's initial products will be a line of intelligent endotracheal (breathing) tubes called SmartTubes product that assess tube location and patency to improve patient safety and reduce costs of care for patients requiring respiratory assistance in the intensive care unit, emergency room and the operating room.

Mr. Kidd noted that the company is developing this as a platform technology. He commented that the company is well positioned to raise additional Venture Capital to fund commercialization of the product.

Ms. Langham moved for approval of a \$500,000.00 award. Ms. Byrn seconded, and the motion passed unanimously.

PDS Biotechnology Corp.
Current Location: Cincinnati, OH
Seeking to Relocate: Indianapolis, IN (Marion County)
\$2,000,000

PDS Biotechnology has developed a simple and novel nanoparticle technology that facilitates the uptake of disease-associated proteins by the immune system and simultaneously generates a strong immune response resulting in eradication of the specific diseased cells without the need for additional immune stimulators. The technology is much simpler, more cost effective, and also eliminates the toxic inflammation associated with the current technologies in development.

Mr. Kidd noted that the company had been actively recruited by a number of other states. He commented that the product being developed by the company had enormous potential as a less toxic, more targeted cancer drug and would be attractive to Venture Capital investment once it had moved beyond the development stage.

Mr. Thompson moved for approval of the \$2,000,000.00 award. Mr. Miller seconded, and the motion passed with Ms. Byrn abstaining.

Kylin Therapeutics, Inc.

West Layfayette, IN (Tippecanoe County)

\$1,264,300

Kylin Therapeutics, Inc. is a leading biotechnology company focused on the development of novel therapeutics. The company employs a revolutionary RNA nanotechnology platform called “pRNA” to exploit the enormous potential of RNA interference (RNAi) to treat many common diseases. This visionary drug delivery (“Trojan horse”) platform has great potential to meet the growing market opportunities for treating cancer, HIV, and other diseases with RNA-based therapeutics by escorting disease fighting drugs directly to the cancer cells thereby reducing or eliminating damage to health cells and tissue.

Mr. Kidd commented that the management team was experienced, skilled at working with universities in transferring their intellectual property to the marketplace and already had the attention of Venture Capital for further developing and commercializing this platform.

Ms. Langham moved for approval of a \$1,264,300.00 award. Ms. Byrn seconded, and the motion passed unanimously.

CSTX, Inc. (CS-Keys)

Indianapolis, IN (Marion County)

\$2,000,000

CS-Keys, Inc. in collaboration with Indiana University Purdue University Indianapolis (Linda H. Malkas and Robert J. Hickey), are developing a cancer therapeutic agent based on foundational comparisons of the normal and malignant ‘synthesome’, particularly the role of PCNA (proliferating cancer nuclear antigen). Studies described in the proposal identify PCNA as a central locus related to the malignant phenotype. CS-Keys now markets an immunohistochemical stain for identifying a form of PCNA that is broadly characteristic of malignancies. The present proposal focuses on the observed effects of an octapeptide derived from the cancer-PCNA form, which appears to disrupt critical DNA-transcription and repair protein-PCNA interactions, leading to death of the cancer cell.

Mr. Kidd noted that the IEDC investment would be matched by investment from a local Venture Capital firm. He commented that the CSTX management team is well positioned to take advantage of Indiana’s strong life sciences infrastructure.

Ms. Byrn moved for approval of a \$2,000,000.00 award. Mr. Thompson seconded, and the motion passed unanimously.

ADJOURNMENT


Mr. Kidd thanked the committee. Chairperson Bym adjourned the meeting at 10:27 a.m.

Respectfully submitted,

Handwritten signature of Bruce Kidd, including the initials "BK" at the end.

Bruce Kidd, Director of Entrepreneurship, Indiana Economic Development Corporation

Approved,

Handwritten signature of Sally R. Bym.
Sally R. Bym, Chairperson

VERIFIED STATEMENT

I, the undersigned Acting Secretary, hereby certify as follows:

At least forty-eight (48) hours (excluding Saturdays, Sundays and legal holidays) before the start of the aforementioned meeting, I (i) posted or had posted at the principal office of the Indiana Economic Development Corporation ("Corporation") public notice of the date, time and place of said meeting and (ii) delivered or had delivered a copy of said notice by electronic mail, facsimile or regular mail to all news media that requested, in writing, such notices by January 1 of this year, all in accordance with Indiana Code § 5-14-1.5-5, and to the extent applicable, Indiana Code § 5-14-1.5-6.1(d). To the extent that the meeting body utilized an agenda for a public meeting, a copy was posted at the entrance to the location of that meeting prior to its commencement.

I affirm, under the penalties of perjury, that the foregoing statements are true and accurate, to the best of my knowledge and belief.



Chad A. Pittman, Acting Secretary



Accelerate Your Business

**NOTICE OF A MEETING OF THE
ENTREPRENEURSHIP COMMITTEE
OF THE BOARD OF DIRECTORS OF
THE INDIANA ECONOMIC DEVELOPMENT CORPORATION**

Notice is hereby given that the Entrepreneurship Committee of the Board of Directors of the Indiana Economic Development Corporation will hold a public meeting on December 11, 2008 at 9:30 a.m., at the AIT Laboratories, 2265 Executive Drive, Indianapolis, Indiana.



**Indiana Economic Development Corporation Entrepreneurship Committee Meeting
December 11, 2008 (9:30-11:00 a.m.)**

- I. Call to Order – Chairperson Sally Byrn
 - a. Recognition of a Quorum
 - b. Recognition of Compliance with Open Door Law
 - c. Reminder to avoid discussion of proprietary IP in the forum

- II. Approval of August 27, 2008 Minutes – Chairperson Sally Byrn

- III. Presentation of 21st Century Research & Technology Fund Applications
 - a. SonarMed
 - b. PDS Biotechnology
 - c. Kylin Therapeutics
 - d. CSTX (CS-Keys)

- IV. Adjournment – Chairperson Sally Byrn